Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › 13 valent Pneumococcal Conjugate Vaccine

13 valent Pneumococcal Conjugate Vaccine

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of 13 valent Pneumococcal Conjugate Vaccine

55 trials tracked of 13 valent Pneumococcal Conjugate Vaccine: 50 in phase 3 or 4 and 6 with published results. The most-cited published study has 42 citations.

55Trials tracked
50Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 8 Phase 3 42 Phase 2 5
  1. Phase 3 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants Completed · 42 cited
  2. Phase 3 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants Completed · 28 cited
  3. Phase 3 Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 Completed · 5 cited
  4. Phase 3 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants Completed · 4 cited
  5. Phase 3 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US Completed · 1 cited
  6. Phase 3 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers Completed
Show 44 more trials
  1. Phase 4 A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers Completed
  2. Phase 4 A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India Completed
  3. Phase 4 Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders Completed
  4. Phase 4 Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults. Completed
  5. Phase 4 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India Completed
  6. Phase 4 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants. Completed
  7. Phase 4 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed
  8. Phase 4 Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease Completed
  9. Phase 3 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants Completed
  10. Phase 3 Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers Completed
  11. Phase 3 Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico Completed
  12. Phase 3 Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults Completed
  13. Phase 3 Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children. Completed
  14. Phase 3 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil Completed
  15. Phase 3 Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants Completed
  16. Phase 3 Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization Completed
  17. Phase 3 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years Completed
  18. Phase 3 Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico Completed
  19. Phase 3 A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older Completed
  20. Phase 3 Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Completed
  21. Phase 3 Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine Completed
  22. Phase 3 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India Completed
  23. Phase 3 Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Completed
  24. Phase 3 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants Completed
  25. Phase 3 Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine Completed
  26. Phase 3 Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan Completed
  27. Phase 3 Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults Completed
  28. Phase 3 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants. Completed
  29. Phase 3 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children Completed
  30. Phase 3 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Completed
  31. Phase 3 Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine Completed
  32. Phase 3 Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS Completed
  33. Phase 3 Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS Completed
  34. Phase 3 Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose. Completed
  35. Phase 3 A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years. Completed
  36. Phase 3 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants. Completed
  37. Phase 3 Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Completed
  38. Phase 3 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants. Completed
  39. Phase 3 Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects Completed
  40. Phase 3 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects Completed
  41. Phase 3 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants Completed
  42. Phase 3 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants Completed
  43. Phase 3 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine Completed
  44. Phase 3 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants Completed

Showing the 50 most-cited and recently-updated of 55 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.